NO20050184L - Nye benzimidazolderivater - Google Patents

Nye benzimidazolderivater

Info

Publication number: NO20050184L
Authority: NO; Norway
Prior art keywords: disorders; nitrogen; obesity; inflammation; disease
Prior art date: 2002-06-28

Application number

NO20050184A

Other languages

English (en)

Norwegian (no)

Inventor

Takehiro Fukami

Akio Kanatani

Norikazu Otake

Minoru Moriya

Yoshio Ogino

Kenji Matsuda

Yoshikazu Nagae

Original Assignee

Banyu Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-28

Filing date

2005-01-12

Publication date

2005-01-12

2005-01-12 Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd

2005-01-12 Publication of NO20050184L publication Critical patent/NO20050184L/no

Links

229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 8
229910052757 nitrogen Inorganic materials 0.000 abstract 5
206010061218 Inflammation Diseases 0.000 abstract 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
230000004054 inflammatory process Effects 0.000 abstract 4
125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 4
208000008589 Obesity Diseases 0.000 abstract 3
208000035475 disorder Diseases 0.000 abstract 3
235000020824 obesity Nutrition 0.000 abstract 3
201000001320 Atherosclerosis Diseases 0.000 abstract 2
206010010904 Convulsion Diseases 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
230000009885 systemic effect Effects 0.000 abstract 2
206010002383 Angina Pectoris Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000008035 Back Pain Diseases 0.000 abstract 1
208000032841 Bulimia Diseases 0.000 abstract 1
206010006550 Bulimia nervosa Diseases 0.000 abstract 1
206010007556 Cardiac failure acute Diseases 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
208000006029 Cardiomegaly Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
208000017164 Chronobiology disease Diseases 0.000 abstract 1
206010010356 Congenital anomaly Diseases 0.000 abstract 1
206010012289 Dementia Diseases 0.000 abstract 1
206010014418 Electrolyte imbalance Diseases 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
208000004930 Fatty Liver Diseases 0.000 abstract 1
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
208000017228 Gastrointestinal motility disease Diseases 0.000 abstract 1
208000010412 Glaucoma Diseases 0.000 abstract 1
201000005569 Gout Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
206010019708 Hepatic steatosis Diseases 0.000 abstract 1
206010020112 Hirsutism Diseases 0.000 abstract 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
201000001431 Hyperuricemia Diseases 0.000 abstract 1
206010058359 Hypogonadism Diseases 0.000 abstract 1
208000007177 Left Ventricular Hypertrophy Diseases 0.000 abstract 1
208000008930 Low Back Pain Diseases 0.000 abstract 1
208000004166 Obesity Hypoventilation Syndrome Diseases 0.000 abstract 1
208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
206010035004 Pickwickian syndrome Diseases 0.000 abstract 1
206010036049 Polycystic ovaries Diseases 0.000 abstract 1
208000005107 Premature Birth Diseases 0.000 abstract 1
206010036590 Premature baby Diseases 0.000 abstract 1
208000037656 Respiratory Sounds Diseases 0.000 abstract 1
201000001880 Sexual dysfunction Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
206010042434 Sudden death Diseases 0.000 abstract 1
206010047163 Vasospasm Diseases 0.000 abstract 1
206010047924 Wheezing Diseases 0.000 abstract 1
230000005856 abnormality Effects 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
208000015114 central nervous system disease Diseases 0.000 abstract 1
208000026106 cerebrovascular disease Diseases 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
210000001072 colon Anatomy 0.000 abstract 1
208000029078 coronary artery disease Diseases 0.000 abstract 1
230000006735 deficit Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
208000010706 fatty liver disease Diseases 0.000 abstract 1
231100000502 fertility decrease Toxicity 0.000 abstract 1
208000020694 gallbladder disease Diseases 0.000 abstract 1
208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
210000004392 genitalia Anatomy 0.000 abstract 1
230000003054 hormonal effect Effects 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
201000010066 hyperandrogenism Diseases 0.000 abstract 1
208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
208000000509 infertility Diseases 0.000 abstract 1
230000036512 infertility Effects 0.000 abstract 1
231100000535 infertility Toxicity 0.000 abstract 1
206010027175 memory impairment Diseases 0.000 abstract 1
208000030159 metabolic disease Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
230000001850 reproductive effect Effects 0.000 abstract 1
208000023504 respiratory system disease Diseases 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
231100000872 sexual dysfunction Toxicity 0.000 abstract 1
201000002859 sleep apnea Diseases 0.000 abstract 1
208000019116 sleep disease Diseases 0.000 abstract 1
231100000240 steatosis hepatitis Toxicity 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20050184A 2002-06-28 2005-01-12 Nye benzimidazolderivater NO20050184L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2002190978		2002-06-28
PCT/JP2003/008161 WO2004002986A2 (en)	2002-06-28	2003-06-26	Novel benzimidazole derivatives

Publications (1)

Publication Number	Publication Date
NO20050184L true NO20050184L (no)	2005-01-12

Family

ID=29996905

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20050184A NO20050184L (no)	2002-06-28	2005-01-12	Nye benzimidazolderivater

Country Status (23)

Country	Link
US (3)	US7105526B2 (is)
EP (1)	EP1517908B1 (is)
CN (2)	CN100560585C (is)
AR (1)	AR040271A1 (is)
AT (1)	ATE506360T1 (is)
AU (1)	AU2003248248B2 (is)
BR (1)	BR0312066A (is)
CA (1)	CA2490722C (is)
DE (1)	DE60336811D1 (is)
DO (1)	DOP2003000662A (is)
EA (1)	EA200500103A1 (is)
EC (1)	ECSP045505A (is)
HR (1)	HRP20041218A2 (is)
IL (1)	IL165810A0 (is)
IS (1)	IS7667A (is)
MX (1)	MXPA04012731A (is)
NO (1)	NO20050184L (is)
PE (1)	PE20040583A1 (is)
PL (1)	PL374693A1 (is)
RS (1)	RS113704A (is)
TW (1)	TW200406411A (is)
WO (1)	WO2004002986A2 (is)
ZA (1)	ZA200409339B (is)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6374762B1 (en) *	1997-10-27	2002-04-23	Correct Craft, Inc.	Water sport towing apparatus
DE60328035D1 (de) *	2002-11-29	2009-07-30	Banyu Pharma Co Ltd	Neue azolderivate
CN1964630A (zh) *	2003-02-13	2007-05-16	耶希瓦大学艾伯塔·爱恩斯坦医学院	通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
CA2518465A1 (en)	2003-03-25	2004-10-14	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
JP2007511467A (ja)	2003-05-14	2007-05-10	タケダサンディエゴインコーポレイテッド	ジペプチジルペプチダーゼインヒビター
KR20060041309A (ko)	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US7838552B2 (en)	2004-06-04	2010-11-23	Forest Laboratories Holdings Limited	Compositions comprising nebivolol
US7803838B2 (en)	2004-06-04	2010-09-28	Forest Laboratories Holdings Limited	Compositions comprising nebivolol
US20060019954A1 (en) *	2004-07-20	2006-01-26	Cedars-Sinai Medical Center	Method for reducing the likelihood of the occurrence of cardiac arrhythmias
EP2374455A3 (en)	2004-08-19	2012-03-28	Vertex Pharmaceuticals Incorporated	Modulators of muscarinic receptors
US7786141B2 (en) *	2004-08-19	2010-08-31	Vertex Pharmaceuticals Incorporated	Dihydrospiroindene modulators of muscarinic receptors
WO2006041922A2 (en) *	2004-10-08	2006-04-20	Dara Biosciences, Inc.	Agents and methods for administration to the central nervous system
RU2007124373A (ru) *	2004-11-29	2009-01-10	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Модуляторы мускариновых рецептеров
US20090012067A1 (en) *	2005-02-14	2009-01-08	Luciano Rossetti	Modulation of Hypothalamic Atp-Sensitive Potassium Channels
MY147393A (en)	2005-09-14	2012-11-30	Takeda Pharmaceutical	Administration of dipeptidyl peptidase inhibitors
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP1940842B1 (en)	2005-09-29	2012-05-30	Merck Sharp & Dohme Corp.	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US7822474B2 (en) *	2005-11-30	2010-10-26	Cedars-Sinai Medical Center	Methods for the prediction of arrhythmias and prevention of sudden cardiac death
AU2006330866A1 (en) *	2005-12-22	2007-07-05	Vertex Pharmaceuticals Incorporated	Modulators of muscarinic receptors
KR20080098070A (ko) *	2006-02-22	2008-11-06	버텍스 파마슈티칼스 인코포레이티드	무스카린성 수용체의 조절제로서의 스피로 축합된 피페리딘
AU2007221214A1 (en)	2006-02-22	2007-09-07	Vertex Pharmaceuticals Incorporated	Modulators of muscarinic receptors
WO2007104053A2 (en) *	2006-03-09	2007-09-13	Pharmacopeia, Inc.	8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN101500565A (zh) *	2006-06-29	2009-08-05	弗特克斯药品有限公司	毒蕈碱性受体的调节剂
ES2397661T3 (es)	2006-08-04	2013-03-08	Isis Pharmaceuticals, Inc.	Composiciones y sus usos dirigidos a la diacilglicerol aciltransferasa 1
AU2007284548A1 (en) *	2006-08-15	2008-02-21	Vertex Pharmaceuticals Incorporated	Modulators of muscarinic receptors
CA2660974A1 (en)	2006-08-18	2008-02-21	Vertex Pharmaceuticals Incorporated	Modulators of muscarinic receptors
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8173629B2 (en)	2006-09-22	2012-05-08	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
JP2010540640A (ja) *	2007-10-03	2010-12-24	バーテックスファーマシューティカルズインコーポレイテッド	ムスカリン作用性レセプターのモジュレーター
WO2009074835A1 (en) *	2007-12-10	2009-06-18	N-Gene Research Laboratories Inc.	Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
JP5435592B2 (ja)	2008-05-28	2014-03-05	ファイザー・インク	ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
MX2011004551A (es)	2008-10-30	2011-05-25	Merck Sharp & Dohme	Antagonistas del receptor de orexina de isonicotinamida.
RU2544010C2 (ru)	2009-02-27	2015-03-10	Энанта Фармасьютикалс, Инк.	Ингибиторы вируса гепатита с
EP2947082A1 (en)	2009-11-10	2015-11-25	Pfizer Inc	N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
WO2011076747A1 (en) *	2009-12-21	2011-06-30	Novartis Ag	Diaza-spiro[5.5]undecanes as orexin receptor antagonists
EP2374731A1 (en)	2010-04-07	2011-10-12	Altachem N.V.	High performance valve
HRP20161178T1 (hr)	2010-09-30	2016-11-04	Pfizer Inc.	N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
ES2546465T3 (es)	2010-10-29	2015-09-23	Pfizer Inc	Inhibidores de N1/N2-lactama acetil-CoA carboxilasa
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
AU2012245996B2 (en)	2011-04-22	2016-09-01	Pfizer Inc.	Pyrazolospiroketone derivatives for use as acetyl-CoA carboxylase inhibitors
BR112014001018A2 (pt)	2011-07-15	2017-01-10	Shionogi & Co	derivado de azabenzimidazol tendo atividade de ativação de ampk
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
RS58514B1 (sr)	2012-06-13	2019-04-30	Incyte Holdings Corp	Supstituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
PH12015502383B1 (en)	2013-04-19	2023-02-03	Incyte Holdings Corp	Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh)	2015-02-20	2020-12-11	美商英塞特公司	作為fgfr抑制劑之雙環雜環
MX2018000412A (es)	2015-07-10	2018-03-14	Ionis Pharmaceuticals Inc	Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AU2019262579B2 (en)	2018-05-04	2024-09-12	Incyte Corporation	Salts of an FGFR inhibitor
HRP20241288T1 (hr)	2018-05-04	2024-12-06	Incyte Corporation	Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
US11098029B2 (en)	2019-02-13	2021-08-24	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (en)	2019-02-13	2020-08-20	Merck Sharp & Dohme Corp.	Pyrrolidine orexin receptor agonists
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021026047A1 (en)	2019-08-08	2021-02-11	Merck Sharp & Dohme Corp.	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en)	2019-10-14	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
JP7832891B2 (ja)	2019-12-04	2026-03-18	インサイト・コーポレイション	Ｆｇｆｒ阻害剤の誘導体
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
BR112023002957A2 (pt)	2020-08-18	2023-04-04	Merck Sharp & Dohme Llc	Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero
US11683717B2 (en) *	2020-11-09	2023-06-20	Celona, Inc.	Method and apparatus for determining wireless MNO coverage and efficiently operating an enterprise wireless communication network
WO2022221170A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CN119119063A (zh)	2021-05-12	2024-12-13	勃林格殷格翰国际有限公司	作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
US11939331B2 (en)	2021-06-09	2024-03-26	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors
CA3220155A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
CN118900840A (zh) *	2022-02-18	2024-11-05	英矽智能科技知识产权有限公司	膜相关的酪氨酸和苏氨酸特异性cdc2抑制激酶(pkmyt1)抑制剂及其用途
WO2025233174A1 (en) *	2024-05-08	2025-11-13	Boehringer Ingelheim International Gmbh	Benzimidazole derivatives as cgas inhibitors

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3914250A (en)	1974-08-01	1975-10-21	American Home Prod	1,4-Diazepino{8 6,5,4-jk{9 carbazoles
JPS608117B2 (ja)	1977-02-08	1985-02-28	財団法人微生物化学研究会	新生理活性物質エステラスチンおよびその製造法
DE2928485A1 (de)	1979-07-14	1981-01-29	Bayer Ag	Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
ZA821577B (en)	1981-04-06	1983-03-30	Boots Co Plc	Therapeutic agents
US4452813A (en)	1981-05-22	1984-06-05	Taiho Pharmaceutical Company Limited	Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative
CA1247547A (en)	1983-06-22	1988-12-28	Paul Hadvary	Leucine derivatives
EP0136976A3 (de)	1983-08-23	1985-05-15	Ciba-Geigy Ag	Verwendung von Phenylpyrimidinen als Pflanzenregulatoren
IE61928B1 (en)	1988-11-29	1994-11-30	Boots Co Plc	Treatment of obesity
US5391571A (en)	1989-11-15	1995-02-21	American Home Products Corporation	Cholesterol ester hydrolase inhibitors
US5112820A (en)	1990-03-05	1992-05-12	Sterling Drug Inc.	Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
US5081122A (en)	1990-03-05	1992-01-14	Sterling Drug Inc.	Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US4973587A (en)	1990-03-08	1990-11-27	Sterling Drug Inc.	3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5013837A (en)	1990-03-08	1991-05-07	Sterling Drug Inc.	3-Arylcarbonyl-1H-indole-containing compounds
FR2692575B1 (fr)	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6472178B1 (en)	1998-02-27	2002-10-29	Regeneron Pharmaceuticals, Inc.	Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5349056A (en)	1992-10-09	1994-09-20	Regeneron Pharmaceuticals	Modified ciliary neurotrophic factors
US5451677A (en)	1993-02-09	1995-09-19	Merck & Co., Inc.	Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5292736A (en)	1993-02-26	1994-03-08	Sterling Winthrop Inc.	Morpholinoalkylindenes as antiglaucoma agents
FR2714057B1 (fr)	1993-12-17	1996-03-08	Sanofi Elf	Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5705515A (en)	1994-04-26	1998-01-06	Merck & Co., Inc.	Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
AU692977B2 (en)	1994-11-07	1998-06-18	Pfizer Inc.	Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands
US5602024A (en)	1994-12-02	1997-02-11	Synaptic Pharmaceutical Corporation	DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5521283A (en)	1995-01-31	1996-05-28	Eli Lilly And Company	Anti-obesity proteins
US5552523A (en)	1995-01-31	1996-09-03	Eli Lilly And Company	Anti-obesity proteins
CA2211656A1 (en)	1995-01-31	1996-08-08	Margret B. Basinski	Anti-obesity proteins
US5554727A (en)	1995-01-31	1996-09-10	Eli Lilly And Company	Anti-obesity proteins
US5552522A (en)	1995-01-31	1996-09-03	Eli Lilly And Company	Anti-obesity proteins
US5559208A (en)	1995-01-31	1996-09-24	Eli Lilly And Company	Anti-obesity proteins
FI973162L (fi)	1995-01-31	1997-09-30	Lilly Co Eli	Liikalihavuutta vastustavia proteiineja
US5552524A (en)	1995-01-31	1996-09-03	Eli Lilly And Company	Anti-obesity proteins
US5605886A (en)	1995-01-31	1997-02-25	Eli Lilly And Company	Anti-obesity proteins
US5532237A (en)	1995-02-15	1996-07-02	Merck Frosst Canada, Inc.	Indole derivatives with affinity for the cannabinoid receptor
US5831115A (en)	1995-04-21	1998-11-03	Abbott Laboratories	Inhibitors of squalene synthase and protein farnesyltransferase
US20020006964A1 (en)	1995-05-16	2002-01-17	Young James W.	Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US5739106A (en)	1995-06-07	1998-04-14	Rink; Timothy J.	Appetite regulating compositions
FR2741621B1 (fr)	1995-11-23	1998-02-13	Sanofi Sa	Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
WO1997020822A1 (en)	1995-12-01	1997-06-12	Novartis Ag	Quinazolin-2,4-diazirines as npy receptor antagonist
AU7692996A (en)	1995-12-01	1997-06-27	Ciba-Geigy Ag	Receptor antagonists
AU7626496A (en)	1995-12-01	1997-06-27	Ciba-Geigy Ag	Heteroaryl compounds
AU1328197A (en)	1995-12-01	1997-06-19	Synaptic Pharmaceutical Corporation	Aryl sulfonamide and sulfamide derivatives and uses thereof
AU7692696A (en)	1995-12-01	1997-06-27	Novartis Ag	Heteroaryl derivatives
TW432073B (en)	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
WO1997029079A1 (en)	1996-02-06	1997-08-14	Japan Tobacco Inc.	Novel compounds and pharmaceutical use thereof
IT1288388B1 (it)	1996-11-19	1998-09-22	Angeletti P Ist Richerche Bio	Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
CA2274594C (en)	1996-12-16	2006-10-10	Banyu Pharmaceutical Co., Ltd.	Aminopyrazole derivatives
DE69822449T2 (de)	1997-01-21	2005-01-27	Smithkline Beecham Corp.	Neue cannabinoidrezeptor-modulatoren
US6251947B1 (en)	1997-02-04	2001-06-26	Board Of Trustees Of The University Of Arkansas	Fungicidal carboxamides
AU735137B2 (en)	1997-02-21	2001-07-05	Bayer Intellectual Property Gmbh	Arylsulphonamides and analogues and their use for the treatment and neurovegetative disorders
US5948777A (en)	1997-03-18	1999-09-07	Smithkline Beecham Corporation	Cannabinoid receptor agonists
FR2761265B1 (fr)	1997-03-28	1999-07-02	Sanofi Sa	Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761266B1 (fr)	1997-03-28	1999-07-02	Sanofi Sa	Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
DE69812096T2 (de)	1997-04-23	2003-10-30	Banyu Pharmaceutical Co., Ltd.	Neuropeptid y rezeptorantagonisten
US6001836A (en)	1997-05-28	1999-12-14	Bristol-Myers Squibb Company	Dihydropyridine NPY antagonists: cyanoguanidine derivatives
SE9702457D0 (sv)	1997-06-26	1997-06-26	Pharmacia & Upjohn Ab	Screening
KR20010021696A (ko)	1997-07-11	2001-03-15	미즈노 마사루	퀴놀린 화합물 및 그의 의약용도
WO1999027965A1 (en)	1997-11-28	1999-06-10	Banyu Pharmaceutical Co., Ltd.	Antihyperlipemic agents
EP1068207A1 (en)	1998-04-02	2001-01-17	Neurogen Corporation	AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES
BR9910583A (pt)	1998-04-29	2001-01-09	Ortho Mcneil Pharm Inc	Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
US6329395B1 (en)	1998-06-08	2001-12-11	Schering Corporation	Neuropeptide Y5 receptor antagonists
WO1999064002A1 (en)	1998-06-11	1999-12-16	Merck & Co., Inc.	Spiropiperidine derivatives as melanocortin receptor agonists
DE19837627A1 (de)	1998-08-19	2000-02-24	Bayer Ag	Neue Aminosäureester von Arylsulfonamiden und Analoga
HN1998000027A (es)	1998-08-19	1999-06-02	Bayer Ip Gmbh	Arilsulfonamidas y analagos
US6358951B1 (en)	1998-08-21	2002-03-19	Pfizer Inc.	Growth hormone secretagogues
US6337332B1 (en)	1998-09-17	2002-01-08	Pfizer Inc.	Neuropeptide Y receptor antagonists
US7417038B1 (en)	1998-10-15	2008-08-26	Imperial Innovations Limited	Methods of treating cachexia
ATE314371T1 (de)	1998-11-10	2006-01-15	Merck & Co Inc	Spiro-indole als y5-rezeptor antagonisten
ES2161594B1 (es)	1998-12-17	2003-04-01	Servier Lab	Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
US6344481B1 (en)	1999-03-01	2002-02-05	Pfizer Inc.	Thyromimetic antiobesity agents
MXPA01009404A (es)	1999-03-19	2004-03-19	Abbott Gmbh & Co Kg	Metodo para tratar trastornos de alimentacion.
FR2792314B1 (fr)	1999-04-15	2001-06-01	Adir	Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU775166B2 (en)	1999-04-22	2004-07-22	H. Lundbeck A/S	Selective NPY (Y5) antagonists
US6340683B1 (en)	1999-04-22	2002-01-22	Synaptic Pharmaceutical Corporation	Selective NPY (Y5) antagonists (triazines)
HK1041263A1 (zh)	1999-05-05	2002-07-05	Ortho-Mcneil Pharmaceutical, Inc.	可用於治疗肥胖和其他疾病的3a，4，5，9b-四氢-1h-苯并[e]吲-2-基胺衍生的神经肽y受体配体
AU778393B2 (en)	1999-05-12	2004-12-02	Ortho-Mcneil Pharmaceutical, Inc.	Pyrazole carboxamides useful for the treatment of obesity and other disorders
CA2377369A1 (en)	1999-06-04	2000-12-14	Merck & Co., Inc.	Substituted piperidines as melanocortin-4 receptor agonists
EP1194421B1 (en)	1999-06-30	2005-10-12	H. Lundbeck A/S	Selective npy (y5) antagonists
WO2001007409A1 (en)	1999-07-23	2001-02-01	Astrazeneca Uk Limited	Carbazole derivatives and their use as neuropeptide y5 receptor ligands
WO2001009120A1 (en)	1999-07-28	2001-02-08	Ortho-Mcneil Pharmaceutical, Inc.	Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
TWI279402B (en) *	1999-08-20	2007-04-21	Banyu Pharma Co Ltd	Spiro compounds having NPY antagonistic activities and agents containing the same
CA2379585C (en)	1999-09-30	2006-06-20	James W. Darrow	Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
ES2277855T3 (es)	1999-09-30	2007-08-01	Neurogen Corporation	Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas.
PL354784A1 (en)	1999-09-30	2004-02-23	Neurogen Corporation	Certain alkylene diamine-substituted heterocycles
WO2001027068A1 (en)	1999-10-13	2001-04-19	Pfizer Products Inc.	Biaryl ether derivatives useful as monoamine reuptake inhibitors
DE19949319A1 (de)	1999-10-13	2001-06-13	Ruetgers Vft Ag	Verfahren zur Herstellung von Arylalkylethern
EP1237875B1 (en)	1999-12-16	2005-08-31	Schering Corporation	Substituted imidazole neuropeptide y y5 receptor antagonists
WO2001056592A1 (en)	2000-02-01	2001-08-09	Novo Nordisk A/S	Use of compounds for the regulation of food intake
WO2001058869A2 (en)	2000-02-11	2001-08-16	Bristol-Myers Squibb Company	Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
JP2001226269A (ja)	2000-02-18	2001-08-21	Takeda Chem Ind Ltd	メラニン凝集ホルモン拮抗剤
WO2001062738A1 (en)	2000-02-22	2001-08-30	Banyu Pharmaceutical Co., Ltd.	Novel imidazoline compounds
GB0004003D0 (en)	2000-02-22	2000-04-12	Knoll Ag	Therapeutic agents
US6531478B2 (en)	2000-02-24	2003-03-11	Cheryl P. Kordik	Amino pyrazole derivatives useful for the treatment of obesity and other disorders
FR2805810B1 (fr)	2000-03-03	2002-04-26	Aventis Pharma Sa	Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805818B1 (fr)	2000-03-03	2002-04-26	Aventis Pharma Sa	Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805817B1 (fr)	2000-03-03	2002-04-26	Aventis Pharma Sa	Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
EP1132389A1 (en)	2000-03-06	2001-09-12	Vernalis Research Limited	New aza-indolyl derivatives for the treatment of obesity
BRPI0109200B8 (pt)	2000-03-14	2021-05-25	Actelion Pharmaceuticals Ltd	compostos e composições farmacêuticas
JP2003527444A (ja)	2000-03-23	2003-09-16	メルクエンドカムパニーインコーポレーテッド	メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
WO2001070708A1 (en)	2000-03-23	2001-09-27	Merck & Co., Inc.	Substituted piperidines as melanocortin receptor agonists
US6600015B2 (en)	2000-04-04	2003-07-29	Hoffmann-La Roche Inc.	Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
EP1142886A1 (en)	2000-04-07	2001-10-10	Aventis Pharma Deutschland GmbH	Percyquinnin, a process for its production and its use as a pharmaceutical
EP1285651B1 (en)	2000-04-28	2010-09-01	Takeda Pharmaceutical Company Limited	Melanin concentrating hormone antagonists
GB0010757D0 (en)	2000-05-05	2000-06-28	Astrazeneca Ab	Chemical compounds
GB0011013D0 (en)	2000-05-09	2000-06-28	Astrazeneca Ab	Chemical compounds
US6432960B2 (en)	2000-05-10	2002-08-13	Bristol-Myers Squibb Company	Squarate derivatives of dihydropyridine NPY antagonists
AU2001263021A1 (en)	2000-05-10	2001-11-20	Bristol-Myers Squibb Company	Alkylamine derivatives of dihydropyridine npy antagonists
US6444675B2 (en)	2000-05-10	2002-09-03	Bristol-Myers Squibb Company	4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
ATE310728T1 (de)	2000-05-11	2005-12-15	Bristol Myers Squibb Co	Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
US7229986B2 (en)	2000-05-16	2007-06-12	Takeda Pharmaceutical Company Ltd.	Melanin-concentrating hormone antagonist
EP1286697A2 (en)	2000-05-17	2003-03-05	Eli Lilly And Company	Method for selectively inhibiting ghrelin action
US6391881B2 (en)	2000-05-19	2002-05-21	Bristol-Myers Squibb Company	Thiourea derivatives of dihydropyridine NPY antagonists
SE0001899D0 (sv)	2000-05-22	2000-05-22	Pharmacia & Upjohn Ab	New compounds
JP2003534377A (ja)	2000-05-30	2003-11-18	メルクエンドカムパニーインコーポレーテッド	メラノコルチン受容体作働薬
ES2291323T3 (es)	2000-06-15	2008-03-01	Schering Corporation	Antagonistas de receptores de trombina.
ES2238458T3 (es)	2000-06-16	2005-09-01	Smithkline Beecham Plc	Piperidinas para uso como antagonistas de los receptores de orexina.
EP1299362A4 (en)	2000-07-05	2004-11-03	Synaptic Pharma Corp	SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
JP2004516239A (ja)	2000-07-06	2004-06-03	ニューロジェンコーポレイション	メラニン凝集ホルモン受容体リガンド
GB0019357D0 (en)	2000-08-07	2000-09-27	Melacure Therapeutics Ab	Novel phenyl guanidines
CN1443198A (zh)	2000-07-24	2003-09-17	阿达纳生物科学有限公司	Ghrelin拮抗剂
JP4180365B2 (ja)	2000-07-31	2008-11-12	エフ．ホフマン−ラロシュアーゲー	ピペラジン誘導体
US6768024B1 (en)	2000-08-04	2004-07-27	Lion Bioscience Ag	Triamine derivative melanocortin receptor ligands and methods of using same
GB0019359D0 (en)	2000-08-07	2000-09-27	Melacure Therapeutics Ab	Novel guanidines
US6680340B2 (en)	2000-08-21	2004-01-20	Merck & Co., Inc.	Anti-hypercholesterolemic drug combination
US20040006120A1 (en)	2000-08-21	2004-01-08	Yates Stephen L	Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
JP2004506687A (ja)	2000-08-23	2004-03-04	メルク　エンド　カムパニー　インコーポレーテッド	メラノコルチン受容体作働薬としての置換ピペリジン類
US6900226B2 (en)	2000-09-06	2005-05-31	Hoffman-La Roche Inc.	Neuropeptide Y antagonists
CA2422013A1 (en)	2000-09-14	2002-03-21	Schering Corporation	Substituted urea neuropeptide y y5 receptor antagonists
HUP0301351A3 (en)	2000-10-13	2007-05-29	Lilly Co Eli	Use of substituted dipeptides as growth hormone secretagogues, process for their preparation and pharmaceutical compositions containing them
AU2167002A (en)	2000-10-16	2002-06-11	Hoffmann La Roche	Indoline derivatives and their use as 5-ht2 receptor ligands
CN1469876A (zh)	2000-10-20	2004-01-21	�Ʒ�	α-芳基乙醇胺及其用作β-3肾上腺素能受体激动剂的用途
AU2002227170A1 (en)	2000-11-03	2002-05-15	Wyeth	Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives
CA2448729A1 (en)	2000-11-20	2002-05-23	Biovitrum Ab	Piperazinyl and piperidyl substituted heterocyclic compounds
NZ525699A (en)	2000-11-20	2005-03-24	Biovitrum Ab	Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor
EP1347982B1 (en)	2000-12-12	2005-11-16	Neurogen Corporation	Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
GB0030710D0 (en)	2000-12-15	2001-01-31	Hoffmann La Roche	Piperazine derivatives
AU3405602A (en)	2000-12-21	2002-07-01	Schering Corp	Heteroaryl urea neuropeptide y y5 receptor antagonists
JP4025200B2 (ja)	2000-12-22	2007-12-19	シェーリングコーポレイション	ピペリジンｍｃｈアンタゴニストおよび肥満の処置におけるそれらの使用
WO2002051232A2 (en)	2000-12-27	2002-07-04	Actelion Pharmaceuticals Ltd.	Novel benzazepines and related heterocyclic derivatives
KR100539143B1 (ko)	2000-12-27	2005-12-26	에프. 호프만-라 로슈 아게	인돌 유도체 및 그의 5-ｈｔ2ｂ 및 5-ｈｔ2ｃ 수용체리간드로서의 용도
EP1368339A1 (en)	2001-01-23	2003-12-10	Eli Lilly & Company	Substituted piperidines/piperazines as melanocortin receptor agonists
ES2247298T3 (es)	2001-01-23	2006-03-01	Eli Lilly And Company	Derivados de piperazina y piperidina como agonistas del receptor de melanocortina.
CA2432988A1 (en)	2001-01-23	2002-08-01	Cristina Garcia-Paredes	Melanocortin receptor agonists
SK10802003A3 (sk)	2001-02-02	2004-05-04	Takeda Chemical Industries, Ltd.	Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok
CA2439152C (en)	2001-02-28	2008-06-17	Merck & Co., Inc.	Acylated piperidine derivatives as melanocortin-4 receptor agonists
US7012084B2 (en)	2001-02-28	2006-03-14	Merck & Co., Inc.	Acylated piperidine derivatives as melanocortin-4 receptor agonists
DE60215132T2 (de)	2001-02-28	2007-08-23	Merck & Co., Inc.	Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten
US6900329B2 (en)	2001-03-21	2005-05-31	Schering Corporation	MCH antagonists and their use in the treatment of obesity
IL157456A0 (en)	2001-03-21	2004-03-28	Pharmacopeia Inc Pharmacopeia	Aryl and biaryl compounds having mch modulatory activity
PL363751A1 (en)	2001-03-22	2004-11-29	Solvay Pharmaceuticals B.V.	4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
AU782148B2 (en)	2001-03-29	2005-07-07	Molecular Design International, Inc.	Beta3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
US6573287B2 (en)	2001-04-12	2003-06-03	Bristo-Myers Squibb Company	2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
ATE460163T1 (de)	2001-04-12	2010-03-15	Pharmacopeia Llc	Arly und diaryl piperidinderivate verwendbar als mch-hemmer
FR2824825B1 (fr)	2001-05-15	2005-05-06	Servier Lab	Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP3715280B2 (ja)	2001-05-21	2005-11-09	エフ．ホフマン−ラロシュアーゲー	ニューロペプチドｙレセプターのリガンドとしてのキノリン誘導体
CA2448080A1 (en)	2001-05-22	2002-11-28	Neurogen Corporation	Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
CA2450579A1 (en)	2001-06-20	2003-01-03	Merck & Co., Inc.	Dipeptidyl peptidase inhibitors for the treatment of diabetes
ES2257555T3 (es)	2001-06-20	2006-08-01	MERCK & CO., INC.	Inhibidores de dipeptidilpeptidasa para el tratamiento de la diabetes.
GB0115517D0 (en)	2001-06-25	2001-08-15	Ferring Bv	Novel antidiabetic agents
JP4357293B2 (ja)	2001-06-27	2009-11-04	スミスクラインビーチャムコーポレーション	ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
ATE380175T1 (de)	2001-06-27	2007-12-15	Smithkline Beecham Corp	Pyrrolidine als dipeptidyl peptidase inhibitoren
CN1723196A (zh)	2001-06-27	2006-01-18	史密丝克莱恩比彻姆公司	作为二肽酶抑制剂的氟代吡咯烷
RU2003105463A (ru)	2001-06-27	2004-11-27	Пробиодруг Аг (De)	Пептидные структуры, пригодные для конкурентного модулирования катализа, осуществляемого дипептидилпептидазой iv
DE60225556D1 (de)	2001-07-03	2008-04-24	Novo Nordisk As	Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
CA2454613A1 (en)	2001-07-05	2003-01-16	Synaptic Pharmaceutical Corporation	Substituted anilinic piperidines as mch selective antagonists
UA74912C2 (en)	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
ITMI20011483A1 (it)	2001-07-11	2003-01-11	Res & Innovation Soc Coop A R	Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
US7115628B2 (en)	2001-07-18	2006-10-03	Merck & Co., Inc.	Bridged piperidine derivatives as melanocortin receptor agonists
AU2002319627A1 (en)	2001-07-20	2003-03-03	Merck And Co., Inc.	Substituted imidazoles as cannabinoid receptor modulators
US6977264B2 (en)	2001-07-25	2005-12-20	Amgen Inc.	Substituted piperidines and methods of use
US6915444B2 (en)	2001-09-12	2005-07-05	Rockwell Automation Technologies, Inc.	Network independent safety protocol for industrial controller using data manipulation techniques
DE60328035D1 (de) *	2002-11-29	2009-07-30	Banyu Pharma Co Ltd	Neue azolderivate

2003
- 2003-06-18 US US10/463,390 patent/US7105526B2/en not_active Expired - Fee Related
- 2003-06-19 AR ARP030102170A patent/AR040271A1/es unknown
- 2003-06-23 PE PE2003000627A patent/PE20040583A1/es not_active Application Discontinuation
- 2003-06-23 DO DO2003000662A patent/DOP2003000662A/es unknown
- 2003-06-25 TW TW092117211A patent/TW200406411A/zh unknown
- 2003-06-26 AU AU2003248248A patent/AU2003248248B2/en not_active Ceased
- 2003-06-26 HR HR20041218A patent/HRP20041218A2/hr not_active Application Discontinuation
- 2003-06-26 EA EA200500103A patent/EA200500103A1/ru unknown
- 2003-06-26 RS YUP-1137/04A patent/RS113704A/sr unknown
- 2003-06-26 CN CNB2006100956720A patent/CN100560585C/zh not_active Expired - Fee Related
- 2003-06-26 CN CNB038153432A patent/CN100427486C/zh not_active Expired - Fee Related
- 2003-06-26 BR BR0312066-0A patent/BR0312066A/pt not_active IP Right Cessation
- 2003-06-26 CA CA2490722A patent/CA2490722C/en not_active Expired - Fee Related
- 2003-06-26 DE DE60336811T patent/DE60336811D1/de not_active Expired - Lifetime
- 2003-06-26 AT AT03761822T patent/ATE506360T1/de not_active IP Right Cessation
- 2003-06-26 WO PCT/JP2003/008161 patent/WO2004002986A2/en not_active Ceased
- 2003-06-26 EP EP03761822A patent/EP1517908B1/en not_active Expired - Lifetime
- 2003-06-26 MX MXPA04012731A patent/MXPA04012731A/es unknown
- 2003-06-26 PL PL03374693A patent/PL374693A1/xx not_active Application Discontinuation
2004
- 2004-11-19 ZA ZA200409339A patent/ZA200409339B/xx unknown
- 2004-12-16 IL IL16581004A patent/IL165810A0/xx unknown
- 2004-12-22 EC EC2004005505A patent/ECSP045505A/es unknown
2005
- 2005-01-12 NO NO20050184A patent/NO20050184L/no not_active Application Discontinuation
- 2005-01-27 IS IS7667A patent/IS7667A/is unknown
2006
- 2006-05-10 US US11/431,274 patent/US7687514B2/en not_active Expired - Fee Related
2009
- 2009-10-26 US US12/605,503 patent/US7803807B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20060205750A1 (en)	2006-09-14
AU2003248248B2 (en)	2009-03-12
AU2003248248A1 (en)	2004-01-19
DOP2003000662A (es)	2003-12-30
IL165810A0 (en)	2006-01-15
WO2004002986A2 (en)	2004-01-08
CA2490722A1 (en)	2004-01-08
WO2004002986A3 (en)	2004-04-22
TW200406411A (en)	2004-05-01
CA2490722C (en)	2012-05-01
DE60336811D1 (de)	2011-06-01
ECSP045505A (es)	2005-03-10
PL374693A1 (en)	2005-10-31
IS7667A (is)	2005-01-27
CN1955178A (zh)	2007-05-02
PE20040583A1 (es)	2004-10-04
EP1517908A2 (en)	2005-03-30
AR040271A1 (es)	2005-03-23
CN100560585C (zh)	2009-11-18
CN100427486C (zh)	2008-10-22
HRP20041218A2 (en)	2005-04-30
US20100048600A1 (en)	2010-02-25
RS113704A (sr)	2007-02-05
ZA200409339B (en)	2006-02-22
EA200500103A1 (ru)	2005-06-30
US7687514B2 (en)	2010-03-30
US20040054177A1 (en)	2004-03-18
MXPA04012731A (es)	2005-03-23
CN1668615A (zh)	2005-09-14
BR0312066A (pt)	2005-03-29
ATE506360T1 (de)	2011-05-15
US7105526B2 (en)	2006-09-12
EP1517908B1 (en)	2011-04-20
US7803807B2 (en)	2010-09-28

Legal Events

Date	Code	Title	Description
2008-01-21	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20050184L (no)	2005-01-12	Nye benzimidazolderivater
JP5363312B2 (ja)	2013-12-11	ピロール誘導体のアトロプ異性体
DE69126251T2 (de)	1997-09-25	Benzensulfonamidderivat
US7285545B2 (en)	2007-10-23	Cytokine inhibitors
DE69901969T2 (de)	2002-10-24	Benzimidazole Derivate als Cyclooxygenase-2 Inhibitoren
EP3233836B1 (fr)	2019-01-30	Dérivés indazoles sulfonamides en tant qu'agonistes inverses du récepteur gamma orphelin associé aux rétinoïdes ror gamma (t)
IL170740A (en)	2011-06-30	Cytokine inhibitors
Kumar et al.	2018	Highly functionalized 2-amino-4H-pyrans as potent cholinesterase inhibitors
JP2006527210A (ja)	2006-11-30	ホルモン感受性リパーゼ阻害剤としてのピリジニルカルバメート
CA2381975A1 (en)	2001-02-22	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
Kang et al.	2013	Antagonism of L-type Ca2+ channels CaV1. 3 and CaV1. 2 by 1, 4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics
KR100703908B1 (ko)	2007-04-05	미세교세포 활성화와 관련된 질병의 치료를 위한1,2-디아릴 벤즈이미다졸
CA2494824A1 (en)	2004-02-19	Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
JP4824576B2 (ja)	2011-11-30	サイトカイン生成のインヒビターとしての１，２，３−トリアゾールアミド誘導体
EP1931642A2 (en)	2008-06-18	Novel pyrimidine carboxamides
US6008224A (en)	1999-12-28	Pyrimidine derivatives
Nam et al.	2008	Design and synthesis of 4-quinolinone 2-carboxamides as calpain inhibitors
Mohamed et al.	2011	Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: Synthesis and biological evaluation
JP2010111657A (ja)	2010-05-20	ピロール誘導体のアトロプ異性体を含有する医薬
CN106279024A (zh)	2017-01-04	一种黄嘌呤氧化还原酶抑制剂及其制备方法与应用
Urbahns et al.	2005	IKCa-channel blockers. Part 2: discovery of cyclohexadienes
Bui et al.	2024	Solvent-free strategy for facile synthesis and cytotoxicity evaluation of benzimidazole derivatives
DE60221152T2 (de)	2008-03-20	Diaryl-1,2,4-triazolderivate als hochselektive cyclooxygenase-2-inhibitoren
Panwar et al.	2020	Transition metal free synthesis of multifunctional thiomethylated-benzenes from aryl/heteroaryl/cyclopropyl methyl ketones
JP2014214118A (ja)	2014-11-17	ピラゾール誘導体またはその塩ならびにそれらを含有する医薬組成物